Press releases

Pharmaleads announces the opening of french sites in its international Phase IIa clinical study of PL37

ANSM (French National Agency for Medicines and Health Products Safety) authorizes the extension of the clinical trial for pain in diabetic neuropathy   Paris, September 28, 2015 – Pharmaleads, the biotech company developing its proprietary Dual Enkephalinase Inhibitors (DENKIs) for the treatment of severe pain, announces today the opening of the first French investigative sites in […] Read full post »

Published on September 28, 2015

Dr. Pierre-André Wicker joins Pharmaleads’ Board of Directors

A prominent specialist in drug development, he will accompany Pharmaleads through the next clinical development stages of PL37, the Company’s first molecule aimed at treating neuropathic pain Paris, July the 2nd 2015 – Pharmaleads, a company specialising in the discovery and early-stage development of small molecule inhibitors of metalloproteases for the treatment of severe pain, […] Read full post »

Published on April 21, 2015

Pharmaleads announces the inclusion of the first patient in Phase IIa study of oral PL37 for pain in diabetic neuropathy

Pharmaleads announces the inclusion of the first patient in Phase IIa study of oral PL37 for pain in diabetic neuropathy World premiere for Dual Enkephalinase Inhibitors (DENKIs), a new class of analgesics and first novel concept for decades in the treatment of chronic pain. Paris, 22 April 2015 – Pharmaleads, a company specialising in the […] Read full post »

Published on April 21, 2015